XII Medical develops minimally invasive neuromodulation therapies for obstructive sleep apnea, enhancing patient access to effective treatment options. Their technology aims to improve clinical outcomes by simplifying the therapeutic process and reducing the need for invasive procedures.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obstructive sleep apnea (OSA) often requires invasive procedures or complex devices, limiting patient access to effective treatment and potentially leading to poor adherence and suboptimal clinical outcomes. Current therapies may be uncomfortable, cumbersome, or require significant lifestyle adjustments.
Solution
XII Medical is developing minimally invasive neuromodulation therapies designed to simplify the treatment of obstructive sleep apnea and improve patient outcomes. Their approach focuses on enhancing patient access to effective treatment options by reducing the need for invasive procedures and complex device management. The technology aims to provide a more comfortable and convenient therapeutic experience, potentially leading to better patient compliance and improved long-term results. By streamlining the therapeutic process, XII Medical seeks to address the limitations of existing OSA treatments and expand the availability of effective solutions.
Target Audience
The primary target audience includes individuals diagnosed with obstructive sleep apnea, as well as physicians and sleep specialists seeking less invasive and more patient-friendly treatment options.
Features
- Minimally invasive neuromodulation techniques
- Simplified treatment protocols for obstructive sleep apnea
- Focus on enhancing patient comfort and convenience
- Designed to improve patient adherence to therapy